Credit Suisse AG cut its stake in shares of Inogen, Inc (NASDAQ:INGN) by 7.4% during the first quarter, Holdings Channel reports. The fund owned 18,062 shares of the medical technology company’s stock after selling 1,433 shares during the period. Credit Suisse AG’s holdings in Inogen were worth $1,401,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of INGN. Parametric Portfolio Associates LLC increased its position in Inogen by 10.3% in the first quarter. Parametric Portfolio Associates LLC now owns 28,102 shares of the medical technology company’s stock valued at $2,180,000 after buying an additional 2,628 shares during the last quarter. Ameriprise Financial Inc. increased its position in Inogen by 9.6% in the first quarter. Ameriprise Financial Inc. now owns 127,985 shares of the medical technology company’s stock valued at $9,927,000 after buying an additional 11,223 shares during the last quarter. Texas Permanent School Fund increased its position in Inogen by 0.3% in the first quarter. Texas Permanent School Fund now owns 11,712 shares of the medical technology company’s stock valued at $908,000 after buying an additional 37 shares during the last quarter. Comerica Bank increased its position in Inogen by 5.4% in the first quarter. Comerica Bank now owns 17,906 shares of the medical technology company’s stock valued at $1,497,000 after buying an additional 919 shares during the last quarter. Finally, BNP Paribas Arbitrage SA increased its position in Inogen by 13.6% in the first quarter. BNP Paribas Arbitrage SA now owns 3,091 shares of the medical technology company’s stock valued at $240,000 after buying an additional 370 shares during the last quarter.

Inogen, Inc (NASDAQ INGN) traded up 0.12% during midday trading on Wednesday, hitting $92.06. The company’s stock had a trading volume of 10,764 shares. The firm has a market cap of $1.91 billion, a P/E ratio of 79.91 and a beta of 1.01. The company’s 50 day moving average price is $94.31 and its 200 day moving average price is $82.87. Inogen, Inc has a 12 month low of $50.24 and a 12 month high of $98.33.

Inogen (NASDAQ:INGN) last issued its quarterly earnings results on Thursday, August 3rd. The medical technology company reported $0.38 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.28 by $0.10. The business had revenue of $64.10 million for the quarter, compared to analysts’ expectations of $59.99 million. Inogen had a net margin of 10.36% and a return on equity of 12.45%. The company’s revenue was up 17.4% compared to the same quarter last year. During the same quarter last year, the company posted $0.25 EPS. Analysts expect that Inogen, Inc will post $1.21 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This piece was first posted by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.watchlistnews.com/inogen-inc-ingn-shares-sold-by-credit-suisse-ag/1494931.html.

Several research firms recently commented on INGN. BidaskClub downgraded Inogen from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Needham & Company LLC increased their target price on Inogen from $96.00 to $108.00 and gave the stock a “strong-buy” rating in a research report on Friday, June 9th. Zacks Investment Research downgraded Inogen from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 11th. J P Morgan Chase & Co increased their target price on Inogen to $102.00 and gave the stock an “overweight” rating in a research report on Monday, June 26th. Finally, Stifel Nicolaus increased their target price on Inogen from $65.00 to $75.00 and gave the stock a “hold” rating in a research report on Wednesday, May 10th. Three investment analysts have rated the stock with a hold rating, one has assigned a buy rating and two have assigned a strong buy rating to the company. Inogen has an average rating of “Buy” and a consensus price target of $91.60.

In other news, EVP Matt Scribner sold 2,500 shares of Inogen stock in a transaction on Friday, June 16th. The shares were sold at an average price of $91.54, for a total transaction of $228,850.00. Following the transaction, the executive vice president now owns 4,833 shares in the company, valued at approximately $442,412.82. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Ray Benjamin M. Anderson sold 4,445 shares of Inogen stock in a transaction on Thursday, May 18th. The stock was sold at an average price of $81.05, for a total transaction of $360,267.25. Following the transaction, the director now owns 4,445 shares in the company, valued at approximately $360,267.25. The disclosure for this sale can be found here. Insiders have sold a total of 87,849 shares of company stock worth $7,894,719 in the last quarter. Corporate insiders own 5.31% of the company’s stock.

About Inogen

Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.

Want to see what other hedge funds are holding INGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Inogen, Inc (NASDAQ:INGN).

Institutional Ownership by Quarter for Inogen (NASDAQ:INGN)

Receive News & Ratings for Inogen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.